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4. SUMMARY 
The human intestinal microbiota represents a complex, densely populated 
ecosystem, which is composed of about 1013-1014 microorganisms of more than 
1000 different bacterial species. The composition of the gastrointestinal 
microbiota comes as a result of natural selection at both the host and microbial 
levels. Despite high inter-individual variation a recent study identified three 
robust bacterial clusters - referred to as enterotypes - that are not nation or 
continent specific.  
Gut microorganisms carry out a variety of beneficial functions for the host such 
as immune modulation, fermenting unused energy substrates and producing 
short-chain fatty acids, regulating the development of the gut and producing 
vitamins. Furthermore they act as a natural barrier against harmful, pathogenic 
bacteria. Although the intestinal microbiota is relatively stable throughout adult 
life, it can be altered by host, diet, environment, bacterial factors and during 
various disease processes or exposure to medical treatment. These changes in 
composition and metabolic function of gut microbiota can influence a host‘s 
physiology and pathology and influence the development of obesity, 
inflammatory bowel diseases, atopic diseases, diarrhea and constipation. 
The aim of this thesis was to investigate shifts in the composition of fecal 
microbiota of oncology patients in response to chemotherapy and antibiotics. 
Abundance and diversity of fecal bacteria were assessed with culture 
independent molecular methods.  
Feces of 17 ambulant patients under immune-suppressive chemotherapy with 
or without concomitant antibiotics were analyzed before and after a 
chemotherapy cycle at four points in time in comparison to 16 gender- and 
agematched healthy controls. Abundance and diversity of all bacteria, 
Bacteroides, bifidobacteria, Clostridium cluster IV and XIVa as well as 
Clostridium difficile were assessed  by targeting 16S rRNA genes with TaqMan 
qPCR, denaturing gradient gel electrophoresis (DGGE) fingerprinting and high-
throughput sequencing. 
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Patients receiving chemotherapy (± antibiotics) harbored significantly less 
bacteria (p< 0.05) than healthy controls. Furthermore absolute numbers of 
bacteria (p = 0.037) were significantly lower following a single treatment of 
chemotherapy, but the microbiota recovered within a few days, sometimes even 
showing a "rebound-effect". The mean percentage of Clostridium cluster XIVa 
decreased significantly after administration of chemotherapy. DGGE 
fingerprinting showed decreased diversity of Clostridium cluster IV and XIVa in 
response to chemotherapy. Clostridium cluster IV diversity was particularly 
affected by antibiotics. In three out of seventeen oncology patients Clostridium 
difficile occurred following chemotherapy. Additionally, a decrease in the genera 
Bifidobacterium, Lactobacillus, Veillonella and Faecalibacterium  was observed. 
In conclusion, chemotherapy treatment alters the composition of fecal 
microbiota and thus may favor colonization with potential pathogens such as C. 
difficile. These changes affect and alter the functions of the GI microbiota and 
may contribute to severe side effects in oncology patients.   
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5. ZUSAMMENFASSUNG 
Die Mikrobiota im menschlichen Darm stellt ein komplexes dicht besiedeltes 
Ökosystem dar, welches aus etwa 1013-1014 Mikroorganismen mit mehr als 
1000 verschiedenen Bakterienarten besteht. Die Zusammensetzung dieser ist 
ein Ergebnis natürlicher Selektion sowohl auf mikrobieller als auch auf 
Wirtsebene. Trotz großer Unterschiede der Mikrobiota zwischen einzelnen 
Individuen, konnte eine aktuelle Studie drei robuste Bakteriencluster 
identifizieren. Diese "Enterotypen" zeigten sich unabhängig der Herkunft der 
Versuchspersonen. 
Die Mikroorganismen im Darm erfüllen eine Vielzahl nützlicher Aufgaben für 
den Wirtsorganismus, wie zum Beispiel die Fermentierung von unverdauten 
Nahrungsbestandteilen und die Produktion von kurzkettigen Fettsäuren. 
Weiters regulieren sie die Entwicklung des Darmepithels und sind an der 
Synthese von Vitaminen beteiligt. Die Mikrobiota dient zudem als natürliche 
Barriere gegen pathogene Bakterien und moduliert das Immunsystem des 
Wirts. Während des Erwachsenenalters ist die Zusammensetzung der 
Darmbakterien relativ stabil, kann jedoch durch verschiedene Faktoren 
beeinflusst werden. Dazu gehören Ernährung und Lifestyle sowie auch 
verschiedene Erkrankungen oder medizinische Behandlungen.  
Veränderungen in der Zusammensetzung und somit auch der metabolischen 
Funktion der Mikrobiota können sich auf die Entwicklung und Pathogenese von 
Übergewicht, atopischen Erkrankungen, Durchfall, Verstopfung und 
entzündlichen Darmerkrankungen auswirken.  
Die vorliegende Diplomarbeit beschäftigt sich mit der Analyse der 
Veränderungen der fäkalen Mikrobiota von Onkologie-Patienten während einer 
Chemo- und Antibiotikatherapie. Ziel war, mittels 16S rRNA basierten 
kulturunabhängigen Methoden den Einfluss von verschiedenen 
Chemotherapeutika auf die Diversität und Menge der Darmbakterien zu 
erfassen. 
 
4 
 
Dazu wurden Stuhlproben von 17 Chemotherapie-Patienten mit oder ohne 
gleichzeitiger Antibiotika-Einnahme mit 16 gesunden Kontrollpersonen 
ähnlichen Alters und Geschlechts verglichen. Untersucht wurden vier 
verschiedene Zeitpunkte vor, während und nach eines Chemotherapiezyklus. 
Absolute und relative Zahlen von Bakterien, Bacteroides, Bifidobakterien, 
Clostridium cluster IV, XIVa und Clostridium difficile im Stuhl wurden mit real 
time PCR (TaqMan-Detektion) erfasst. Diversitätsanalysen erfolgten mit DGGE 
(Denaturierungs-Gradientengel-Elektrophorese) und high-throughput 
Seqenzierung. 
Chemotherapiepatienten (± Antibiotika) zeigten im Vergleich zur gesunden 
Kontrollgruppe signifikant weniger Gesamtbakterien (p <0,05). Auch direkt nach 
einem Chemotherapiezyklus waren die absoluten Bakterienzahlen deutlich 
verringert (p = 0.037) und zudem der relative Anteil von Clostridium cluster XIVa  
signifikant erniedrigt. Dennoch konnte sich die Mikrobiota nach Beendigung der 
Chemotherapie meist wieder auf das Ausgangsniveau und bei manchen 
Patienten auch darüber hinaus erholen. 
DGGE fingerprinting zeigte nach einer chemotherapeutischen Intervention eine 
verringerte Diversität von Clostridium Cluster IV und XIVa, cluster IV wurde 
zusätzlich durch gleichzeitige Antibiotika-Einnahme beeinflusst. Bei drei der 17 
Onkologie-Patienten konnte nach der Chemotherapie ein Vorkommen von 
Clostridium difficile beobachtet werden. Gleichzeitig zeigten die Genera 
Bifidobacterium, Lactobacillus, Veillonella und Faecalibacterium prausnitzii 
einen Abfall.  
Diese Ergebnisse zeigen, dass Chemotherapeutika einen erheblichen Einfluss 
auf die Zusammensetzung der fäkalen Mikrobiota haben können. Durch diese 
Veränderungen kann die Besiedlung mit potentiell pathogenen Bakterien wie 
Clostridium difficile begünstigt und die nützlichen Funktionen der Darmbakterien 
beeinträchtigt werden, was im Verlauf einer Chemotherapie zu schweren 
Nebenwirkungen beitragen kann.  
5 
 
6. OBJECTIVES 
The human intestinal microbiota is composed of about 1013-1014 
microorganisms with an estimated mass of 1-2 kg [LEY et al., 2006] belonging 
to more than 1000 different bacterial species. A substantial part of these 
species are still to be described. The microbiota represents a complex, densely 
populated ecosystem, where strict principles regarding growth control and 
community life must exist to maintain a healthy milieu [STEINHOFF, 2005].   
For health it is very important to have a balanced ratio of the different bacterial 
populations. Adapted to the environment gut bacteria perform a variety of tasks 
in the different intestinal segments from immune modulation to the supply of 
vitamin K1. Furthermore, they produce short-chain fatty acids which nourish the 
intestinal mucosa, act antiphlogistic on the one hand and protect against colon 
cancer on the other [HAMER et al., 2008]. Also undisputed is scientific evidence 
regarding the influence of metabolites on the psyche and the frame of mind 
[BRAVO et al., 2011]. 
The healthy gastrointestinal microbiota is more or less constant, but infectious 
diseases, severe psychological stress or poor nutrition can disturb the orderly 
interactions of the bacteria in the gut and allow overgrowth of potential 
pathogens like Clostridium difficile [VAN DER WAAIJ, 1989]. Chemotherapy 
and the use of antibiotics may also disrupt the ecological balance [NYHLEN et 
al., 2002]. As a matter of fact antimicrobial therapy can result in antibiotic-
associated diarrhea (AAD) [KONING et al., 2008] and increases the risk of a 
Clostridium difficile infection [HENSGENS et al. 2011]. 
Well known side-effects of cancer treatments are immunosuppression and 
gastrointestinal disturbances like constipation, diarrhea and mucositis. Yet, little 
research has been conducted on the underlying mechanism and the shifts in 
microbiota. 
The purpose of this thesis was to investigate changes in the composition of 
fecal microbiota of patients under chemotherapeutical administration with or 
without antibiotics at four different points in time in comparison to a healthy 
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control group. Sample times were before and after a single chemotherapeutic 
cycle, so qualitative and quantitative changes were studied over the course of 
time. The aim was to clarify how chemotherapeutic agents influence fecal 
bacteria by assessing abundance and diversity with culture independent 
methods. Dominant bacteria, Bacteroides, bifidobacteria, Clostridium cluster IV, 
Clostridium cluster XIVa and Clostridium difficile were analysed. 
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7. INTRODUCTION 
7.1. The human gut 
In the human organism the intestinal mucosa represents the largest boundary to 
the environment. At the same time it is estimated that the human intestine 
accommodates 10 times more bacterial cells than body cells [SAVAGE, 1997] 
and 100 times more genes than the human genome [BÄCKHED et al., 2005]. 
The density of microorganisms increases from the mouth to the anus. In total, 
1014 prokaryotic organisms live in the intestine. As shown in figure 1 the 
bacterial numbers range from 1011 cell/g content in the ascending colon to 107-8 
in the distal ileum and 102-3 in the proximal ileum und jejunum [NEISH, 2009]. 
 
The intestinal microbiota can be pictured as a ―forgotten organ‖, since its 
metabolic activity is equal to a virtual organ [O'HARA & SHANAHAN, 2006]. 
The microorganisms carry out a variety of beneficial functions for the host, such 
as immune modulation, fermenting unused energy substrates and producing 
short-chain fatty acids, regulating the development of the gut, producing 
vitamins and furthermore, they act as a natural barrier against harmful, 
pathogenic bacteria. When considering the importance of microbial functions to 
Figure 1: Population composition and numbers in 
cell/g content in the intestine [DEIBERT et al., 2010] 
8 
 
the host, the relationship between the human host and its intestinal microbes 
must in many cases be termed symbiotic rather than commensal. 
The community within the human gut is extraordinarily diverse. Although 
bacteria predominate, it also contains archaea, yeasts and filamentous fungi 
[RAJILIC‘-STOJANOVIC‘ et al., 2007]. Various recent studies [REYES et al., 
2010; MINOT et al., 2011] investigated viruses as another important 
component. ZHANG et al. found more than 1200 viral genotypes with a density 
of up to 109 virions per g of dry material in human faeces [ZHANG et al., 2006]. 
The majority of the bacterial species in the human gut cannot be cultured, but 
with modern molecular methods such as sequencing of 16S ribosomal RNA 
from amplified nucleic acid it is possible to identify and classify bacteria. The 
composition of the gastrointestinal microbiota comes as a result of natural 
selection at both the host and microbial levels [O'HARA & SHANAHAN, 2006]. 
Bacteroidetes and Firmicutes represent with 60-90% of the total population the 
two dominant species [NEISH, 2009]. Frank et al. assigned with two other 
studies 98% of 16S rRNA sequences to only four bacterial phyla: Firmicutes 
(64%), Bacteroidetes (23%), Proteobacteria (8%) and Actinobacteria (3%). The 
remaining 2% were comprised of Fusobacteria and the TM7 phylum [FRANK et 
al., 2007]. 
 
7.2. Structural changes from infants to the elderly  
The gastrointestinal tract is assumed to be sterile until birth. When the foetus 
passes the birth canal the bacterial colonization starts. Many factors like age of 
the infant, mode of delivery, dietary regime and antimicrobial treatment have an 
influence on the highly dynamic infant microbiota composition [PENDERS et al., 
2006]. 
The micro-organisms that colonize the infant during birth descend from the 
maternal fecal, the vaginal flora and also from the surrounding environment 
[WALLACE et al., 2011]. The initial exposure of infants born by caesarian is 
mainly from the surrounding environment. However a recent study showed that 
the mode of delivery (vaginal-delivery or caesarian-delivery) and the feeding 
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habit (breast-fed or total-formula-fed) has not the big impact on the composition 
of gastrointestinal microbiota as always presumed. All kind of infants had similar 
microbial compositions by 1 month of age. This observation suggested that the 
colonization process may start during gestation [HONG et al., 2010].  
The first colonizers of the large intestine are facultative anaerobic strains such 
as Escherichia coli and Streptococcus spp.. The second generation of  
colonizing bacteria depend mainly on the feeding profile of the infant  
[WALLACE et. al, 2011]. Generally anaerobe genera such as Bifidobacterium, 
Bacteroides, Clostridium and Eubacterium follow. 
Figure 2 shows the prevalence of microbial groups at day 4 and day 120 in 
infants not exposed to medical interventions [EGGESBØ et al., 2011]. Almost all 
Figure 2: Prevalence of microbial groups at day 4 and day 120. 
Bacterial groups are ordered by mean prevalence at day 4. The p-
values are calculated based on 81 infants with data for both days. **** 
P-value <0.0001, *** p-value <0.001, ** p-value<0.01 and * p-
value<0.05  [EGGESBØ et al., 2011].   
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infants harbored gamma-Proteobacteria and Bifidobacterium. Associations 
between bacterial composition of day 4 and day 120 were observed, suggesting 
that early gut microbiota may influence later microbiota [EGGESBØ et al., 
2011]. 
Breast milk is the first dietary exposure for the infant. Besides a unique 
combination of proteins, lipids, minerals and vitamins human milk also contains 
communities of bacteria and provides significant quantities of prebiotic 
carbohydrates other than lactose. Whereas previous works has identified 
lactobacilli and bifidobacteria as major phylotypes [MARTIN et. al, 2009, 
COLLADO et al., 2009], Hunt et al. observed Streptococcus and 
Staphylococcus as common genera in breast milk [HUNT et al., 2011]. The 
oligosaccharides in milk, which are not digestible by human infants, serve as 
prebiotics and are selectively fermented by the gut microbiota [GERMAN et al., 
2008], providing bioactive compounds responsible for a wide range of beneficial 
effects for the infant gut [LARA-VILLOSLADA et al., 2007]. The final acquisition 
of the infant gastrointestinal microbiota takes places at weaning and a complex 
gut microbiota emerges [WALLACE et al., 2011]. 
Under normal circumstances the intestinal microbiota is relatively stable 
throughout adult life, but infectious diseases, medical administration, stress or 
poor nutrition can have adverse effects on the balanced interactions of the 
bacteria in the gut. In addition, age-related changes in the gastrointestinal tract, 
host immune system reactivity and altered nutrition interfere with the GI 
microbiota. Increased thresholds for smell and taste and the consequent 
reduced appetite, masticatory dysfunction and swallowing difficulties often result 
in a unbalanced, narrow diet in elderly people. With aging the amylolytic activity 
decreases as well as the intestinal motility, the latter implicating an increased 
retention time, constipation and fecal impaction [WOODMANSEY, 2006]. 
Furthermore, the composition of the gastrointestinal microbiota changes in 
elderly hosts. A general reduction in species diversity within most bacterial 
groups as well as a decrease in total numbers of beneficial organisms such as 
lactobacilli, bifidobacteria and Bacteroides was observed, whereas an increase 
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in the number of facultative anaerobes occurred [GUIGOZ et al., 2008; 
WOODMANSEY, 2006; ZWIELEHNER et al., 2009].  
The decrease of relative abundances of important sub-dominant populations 
such as bifidobacteria and Clostridium cluster IV could have considerable 
consequences for the elderly host because of modified metabolic activities, e.g. 
a reduced formation of SCFAs, altered barrier function of the GI epithelium and 
a modified epithelial cell maturation and maintenance (ZWIELEHNER et al., 
2009].  
In summary, these changes in number and diversity of gastrointestinal bacteria, 
diet, digestive physiology such as intestinal transit time, may implicate impaired 
immune functions, increased putrefaction in the colon and a greater 
susceptibility to disease [WOODMANSEY, 2006]. 
 
7.3. Core microbiome vs. enterotypes 
Microbes in the human gastrointestinal tract undergo selective pressure from 
the host as well as from microbial competitors, which results in a homeostasis 
of the ecosystem in which some species occur in high and many in low 
abundance [ARUMUGAM et al., 2011]. However, some low abundance species 
perform specialized and important functions for the host.  
Various studies based on 16S ribosomal-RNA show a high microbial diversity 
within and between individuals. However, the knowledge about the phylum level 
composition in the human gastrointestinal tract is emerging. At the same time, 
the variation in species composition and gene pools within the human 
population is less clear [ARUMUGAM et al., 2011].  
It was thought that there could be a 'core microbiota' of shared microorganisms 
in the gastrointestinal tracts of different individuals [TURNBAUGH et al., 2007], 
but Tap et al. showed in a later work that there is rather a identifiable 'core 
microbiome' of commonly shared functional gut genes than a core of commonly 
shared microorganisms [TAP et al., 2009]. 
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Previous work shows that only one-third of the bacterial gene clusters that were 
conserved across 124 different individuals from Nordic and Mediterranean 
European origins could be associated with a broad functional assignment [QIN 
et al., 2010]. 
Finally, Arumugam et al., by combining 22 sequenced, fecal metagenomes of 
individuals from four countries, demonstrated the existence of three enterotype 
clusters that were not nation- or continent-specific, but vary in species and 
functional composition [ARUMUGAM et al., 2011]. Each of these three 
enterotypes are identifiable by the variation in the levels of one of three genera: 
Bacteroides (enterotype 1), Prevotella (enterotype 2) and Ruminococcus 
(enterotype 3). Enterotype 1 was enriched in Bacteroides and seemed to derive 
energy primarily from carbohydrates and proteins through fermentation. 
Enterotype 2 was enriched in Prevotella and the co-occuring Desulfovibrio, 
which can act in synergy to degrade mucin glycoproteins that are present in the 
mucosal layer of the gut. Enterotype 3 was the most frequent and is enriched in 
Ruminococcus as well as co-occurring Akkermansia, both known to comprise 
species able to degrade mucins. Enterotypes 1 and 2 were capable of 
biosynthesis of different vitamins. It still needs further research on  
environmental or even genetic factors that are causing the clustering. 
 
7.4. Intestinal microbiota and its functions 
Of the varied strategies and methods applied to study the function of the 
microbiota, perhaps the use of germ-free animals has offered the most 
revealing insights [GRENHAM et al., 2011]. Gut bacteria can be categorized as 
either beneficial or potentially pathogenic depending on their metabolic activities 
and fermentation end products. Health promoting effects of the microbiota may 
include the following: immunostimulation, growth inhibition of potential 
pathogens, improved digestion and absorption, vitamin synthesis, removal of 
cholesterol from the enterohepatic cycle, and decreased gas distension. 
Harmful effects include carcinogen production, intestinal putrefaction, toxin 
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production, diarrhea/constipation, liver damage, and intestinal infections. 
[WALLACE et al., 2011].  
If the gut microbiota is in good balance then it has mainly beneficial effects for 
the host and regulates major epithelial and immune functions of importance for 
gut health and health (see figure 3) [SHARMA et al., 2010; CHUNG & CASPER, 
2010]. It prevents colonization of potentially pathogenic microorganisms by 
competing for nutrients and epithelial sites and regulates the mucosal immune 
system, not only educating the naive infant immune system but also serving as 
a relevant source of immune stimulators throughout life [ROUND & 
MAZMANIAN, 2009]. The GI microbiota is important for the maintenance of an 
intact GI barrier, which seems to be closely related to infectious, inflammatory 
and allergic diseases [GROSCHWITZ & HOGAN, 2009]. 
The microbiota also contributes to energy homeostasis and has an important 
role in supporting digestion and host metabolism. There are two main 
mechanisms by which it can maximize nutrient availability, either by fermenting 
indigestible food substances and so providing energy or by modulating 
absorption [SEKIROV et al., 2010]. A significant energy source for humans is 
the bacterial metabolism of dietary fiber to short-chain fatty acids such as 
butyrate, propionate and acetate. SCFAs in general and butyrate in particular 
increase growth of intestinal epithelial cells, control their proliferation and 
differentiation and enhance the growth of beneficial bacteria such as lactobacilli 
and bifidobacteria.  
Figure 3: Functions of the intestinal microbiome [GRENHAM et al., 2011] 
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Furthermore, the gut microbiome is involved in synthesizing micronutrients, in 
breaking down dietary toxins and carcinogens and is crucial for normal GIT 
motility. Finally, it is responsible for producing antimicrobial compounds 
[SEKIROV et al., 2010], regulating fat storage and influencing angiogenesis in 
the intestine and epithelial turnover.  
It has been shown that the gut microbiome reports to the brain via hormones 
and Nervus vagus and, in this way, may affect mood, behaviour and 
corresponding neurochemical changes in the brain [TSURUGIZAWA et al., 
2009; NEUFELD et al., 2011]. 
The GI microbiota and the permanent challenge with bacterial antigens are 
crucial for the normal development and function of the gut associated lymphoid 
tissue (GALT) [BOUSKRA et al., 2008; ROUND & MAZMANIAN; 2009].  
 
7.5. Bacterial communities 
The microbial community within the human gut is extraordinarily diverse. 
Although bacteria predominate, it also contains archaea, yeasts and 
filemantous fungi. Bacteroidetes and Firmicutes represent with 60-90% of the 
total population the two dominant phyla [NEISH, 2009]. In this work the focus 
was on Bacteroides, bifidobacteria, Clostridium cluster IV, XIVa and Clostridium 
difficile, which are described in more detail in the following section: 
7.5.1. Bacteroides 
Bacteroides are Gram-negative, non-spore-forming, obligate anaerobic and rod-
shaped bacteria and are commonly found in oral, respiratory, intestinal, and 
urogenital cavities of humans and animals. Some strains such as B. fragilis can 
cause potentially fatal abscesses and other infections [LI et al., 2002; 
PAPANILAKOU et al., 2011]. Bacteroides spp. are fibrolytic and involved in 
numerous important metabolic activities including carbohydrate fermentation 
and butyrate production. They possess broad glycan-degrading abilities and 
use a series of membrane protein complexes for catabolism of many complex 
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carbohydrates [MARTENS et al. 2011]. Previous studies have suggested that 
Bacteroides are characteristic for the 'ageing microbiota' [MARIAT et al., 2009; 
ZWIELEHNER et al., 2009]. There are contradictory results regarding the link 
between higher Bacteroides levels and obesity. 
7.5.2. Bifidobacteria 
Bifidobacteria are Gram-positive, anaerobic, branched rod-shaped bacteria. 
They belong to the phylum Actinobacteria and are commonly found in the 
gastrointestinal tract, vagina and mouth of mammals. Bifidobacteria ferment 
sugars in the intestine to produce acetic and lactic acid. Some bifidobacteria 
exhibit a variety of immune modulatory effects, such as being anti-inflammatory, 
increasing IgA secretion, and moderating allergy [HIRAMATSU et al., 2007; 
OUWEHAND, 2007] and have been suggested to inhibit colon cancer [SINGH 
et al., 1997]. Furthermore, D'Aimmo et al. suggested that certain bifidobacteria 
may contribute to folate uptake [D'AIMMO et al., 2012]. 
7.5.3. Clostridium cluster IV, Clostridium cluster XIVa, Clostridium difficile 
Clostridia are group of Gram-positive spore-forming anaerobe to microaerophilic 
species and belong to the phylum Firmicutes. They are phylogenetically and 
metabolically highly diverse bacteria [MAUKONEN et al., 2006] divided into 19 
clusters [COLLINS et al., 1994]. The predominant intestinal Clostridia belong 
mainly to clusters XIVa [Clostridium coccoides–Eubacterium rectale (Erec) 
group] and IV (Clostridium leptum group) [ECKBURG et al., 2005]. They contain 
saccharolytic and/or proteolytic species and are involved in metabolizing 
various substrates, resulting in a variety of metabolites such as fatty acids and 
gases. Especially short chain fatty acids formed by microbial fermentation such 
as butyrate have an important effect on colonic health [MAUKONEN et al., 
2006].   
Within Clostridium cluster IV, the cluster F. prausnitzii is the most frequent 
and abundant [LAY et al., 2007], which has been shown to exhibit anti-
inflammatory effects on cellular and TNBS colitis models [SOKOL et al., 2007].  
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Clostridium cluster XIVa contains butyrate-producing organisms such as 
Roseburia and also mucine-degrading strains such as some Ruminococcus 
species. 
Anaerobic Clostridium difficile is the most common cause of antibiotic-
associated diarrhea in hospitals and other healthcare facilities [ARVAND et al., 
2012]. The bacterium can also be carried asymptomatically. In the past decade 
a dramatically increased occurrence and severity of Clostridium difficile 
infections (CDI) has been noted. Individuals who fail to mount an immune 
response to C. difficile toxin are succeptible to infection. Thus, 
immunosuppressed patients having a blunted ability to mount immune 
responses, are at a greater risk for infection [BINION, 2011]. Schalk et al. found 
Clostridium difficile-associated diarrhea as a frequent complication in patients 
with acute myeloid leukaemia [SCHALK et al., 2009]. Also, antibiotic exposure, 
that disturbs the normal intestinal flora, allows C. difficile to flourish and 
potentially result in antibiotic-associated diarrhea (AAD) [COHEN et al. 2010]. 
 
7.6. Microbiota in health and disease and modulation 
The composition of the gastrointestinal microbiota can be altered by host, diet, 
environment, and bacterial factors and during various disease processes or 
exposure to medical treatment. On the other hand, changes in composition and 
metabolic function of gut microbiota can influence a host‘s physiology and 
pathology. Previous studies indicate that microbiota influence the development 
of obesity, inflammatory bowel diseases, atopic diseases, diarrhea and 
constipation [MAY et al., 2009; SOKOL et al.; 2008 & 2009, QIN et al., 2008]. A 
large body of evidence supports also a relationship between bacteria, bacterial 
activities and human colorectal cancer [BOLEIJ &TJALSMA, 2012].  
It is now increasingly accepted that obesity is associated with substantial 
changes in composition and metabolic function of gut microbiota. In contrast to 
earlier studies the ratio of Firmicutes: Bacteroidetes as main link to obesity is 
likely to be outdated. A recent study suggested that not the ratio of Firmicutes: 
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Bacteroidetes is important, but rather the amount of SFCA produced 
[SCHWIERTZ et al., 2010]. Kalliomäki et al. hypothesized that early differences 
in fecal microbiota composition in children may predict overweight. However, 
further research has to be conducted in the underlying mechanisms of 
microbiota and weight gain [KALLIOMÄKI et al., 2008]. 
Therapeutic bacteria could presumably provide the same beneficial functions 
and activities that have evolved for the healthy microbiota. Probiotics are live 
microorganisms which when administered in adequate amounts confer a health 
benefit on the host. Prebiotics are defined as non-digestible dietary 
carbohydrates, which are able to survive stomach acid and bile, stimulate the 
growth and metabolism of endogenous gut bacteria and are safe for human 
consumption. It has been reported that probiotics and prebiotics can aid 
systemic and mucosal immune function, improve intestinal barrier function, 
modulate gut micro-ecology, and exert metabolic effects on the host and thus, 
ameliorate chronic intestinal inflammation, diarrhea, constipation, irritable bowel 
syndrome, atopic dermatitis, sepsis, food allergies, vaginitis and liver disease 
[WALLACE et al., 2011]. 
However, studies regarding the proposed effect of probiotics and prebiotics are 
still contradictory and further research is needed. The key to the effective use of 
probiotics in treating human disease is to match the correct probiotic strain with 
the desired clinical outcome [WALLACE et al., 2011]. 
 
7.7. Microbiota in chemotherapy and antibiotic treatment 
Pathological conditions such as infections, antibiotic therapy, proton-pump 
inhibitory medication and immune suppression also result in shifts in microbiota, 
which cause severe side effects in patients. Cytotoxic chemotherapy is a 
common treatment for malignancies that has been in use for many years. It can 
cause functional and structural changes to the GIT and damages the mucosal 
cells [CUNNINGHAM, 1985]. Diarrhea and constipation are common harmful 
secondary effects, furthermore mucositis is a major problem induced by the 
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cytotoxic effects of cancer therapy and radiotherapy [GIBSON et al., 2006; 
STRINGER et al., 2007]. 
Previous work have been conducted on the effect of chemotherapy and 
antibiotics on intestinal microbiota, but there is still further research to be done 
on the direct effects, how these therapies interfere with the composition of the 
native gut microbiota. All studies found decreased numbers of total bacteria 
after cycles of chemotherapy. Van Vliet et al. additionally observed an 
increased risk of infection and overgrowth with potential pathogenic species 
such as C. difficile following chemotherapeutic and antibiotic treatment [VAN 
VLIET et al. 2009]. Buffie et al. showed profound alterations of intestinal 
microbiota following a single dose of clindamycin - a lincosamide antibiotic - and 
a resulting sustained susceptibility to Clostridium difficile-induced colitis 
[BUFFIE et al., 2011]. Huang et al. monitored alteration in microbiota in children 
with acute lymphoblastic leukemia receiving a high-dose methotrexate 
(HDMTX) chemotherapy. Total bacteria load and the amount of bifidobacteria, 
Lactobacillus and E. coli decreased significantly compared with the control 
group [HUANG et al., 2012]. 
In conclusion, chemotherapy directly affects the microbiota composition, 
damages the rapidly generated mucosal cells of the GI and antibiotic treatment 
disrupts the ecological balance, which might influence colonization resistance. 
Thereby the risk of infection increases and allows potential pathogens such as 
Clostridium difficile to grow [NYHLEN et al., 2002; VAN VLIET et al., 2009].  
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8. MATERIAL AND METHODS 
8.1. Study design  
Figure 4 illustrates used methods and study design of this thesis. The statistical 
methods of analysis are discussed in more detail in chapter 08.10. 
 
8.2. Study participants 
This study included a study population of 33 participants. The 
Sozialmedizinisches Zentrum Ost (SMZO) in Vienna provided faecal samples 
from 17 patients under immune-suppressive, anti-malignant chemotherapy with 
or without antimicrobial therapy (aged 59 ± 13 y, 92 BMI 27 ± 6). The gender 
ratio was 47% female and 53% male. Four samples of each patient were taken 
within two weeks before and after a single chemotherapeutic dose. 14 out of 17 
patients already had one or more chemotherapies before this treatment cycle, 
for three patients it was the first bout of chemotherapy. As seen in table 1 five 
individuals additionally suffered from diverse other diseases like hypertension, 
Figure 4: Study design and used methods 
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Name Diagnosis Chemotherapeutic treatment Antimicrobial treatment Additional diseases
P01 urothel carcinoma gemcitabine, cisplatinum
P02 plasmocytoma, multiple myeloma bortezomib, dexamethasone rheumatism
P03 Non-Hodgkin lymphoma bendamustine diabetes II, adipositas, hypertension
P04 ovarian fibroma taxol, carboplatin levofloxacin
P05 multiple myeloma bortezomib, doxorubicin, dexamethasone cotrimoxazole osteoporosis
P06 mamma carcinoma
pegylated liposomal doxorubicin 
hydrochloride, gemcitabine
P07 Non-Hodgkin lymphoma
high dose radiation therapy and peripheral 
blood stem cell transplant, cytarabine, 
etoposid, carmustine
cotrimoxazole, piperacillin, 
tazobactam 
P08 monozytic leukemia cytarabine, idarubicin
cotrimoxazole, piperacillin, 
tazobactam 
P09 acute leukemia
high dose Ara-C, radiated erythrocyte 
concentrate, cytarabine piperacillin , tazobactam 
P10 Non-Hodgkin lymphoma ifosamid, etoposid, methotrexat levofloxacin
P11 Acute lymophoblastic leukemia cytarabine, methotrexat adipositas, hypertension
P12 small intestinal tumor cetuximab
P13 rectal tumor capecitabine, oxaliplatin
P14 thymus tumor taxol, carboplatin, bevacizumab, radiation
P15 Acute lymophoblastic leukemia
cyclophosphamide, methotrexate, 
doxorubicin, cytarabine, vincristine NIDDM
P16 Acute lymophoblastic leukemia cytarabine, mitoxantrone
P17 colon tumor
oxaliplatin, capecitabine, bevacizumab, 
irinotecan, monoclonal antibodies
obesity, diabetes mellitus type II (NIDDM), rheumatism and osteoporosis. Types 
of malignancies as well as chemotherapeutic and additional treatments like 
antibiotics were reported by anonymous medical records. Six patients were 
diagnosed with a form of leukemia, three persons suffered from a Non-Hodgkin 
lymphoma. Other malignancies were bowel cancers, bladder cancer, mamma 
carcinoma, multiple myeloma and ovarian arrhenoblastoma. The 
chemotherapeutical administration included bendamustin, bortezomib, 
cetuximab, cytarabin, dexamethosane, doxorubicin, etoposid, gemcitabine, 
irinotecan and melphalan. Six Patients (P04, P05, P07, P08, P09, P10) 
furthermore received antibiotics (Table 1). 
The control group consisted of 16 healthy individuals (aged 65 ± 18 y, BMI 24 ± 
5), 56% female, 44% male. To consider the natural fluctuations of a healthy 
microbiota in the research, a part of the control group had to provide several 
samples. Stool samples of C01-C07 were collected at three or four points in 
time within two weeks, while samples of C08-C16 were collected just once. 
Exclusion criteria for healthy controls were antimicrobial treatment, 
chemotherapeutic administration and the intake of pre- and probiotics at least 
three months before sample collection. 
Table 1: Oncology patients, malignancies, additional diseases and treatments 
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All subjects had to answer a questionnaire assessing their dietary habits, body 
constitution (age, gender, body length, weight), health status (chronic and acute 
diseases) and life-style aspects (e.g. alcohol consumption and physical activity). 
All study participants gave written informed consent. Approval was obtained 
from the Viennese Human Ethics committee. 
 
8.3. Sampling and DNA extraction 
Stool samples were immediately brought to the laboratory and stored at –70°C 
after sampling. 180-220 mg of each frozen sample were measured out and 
homogenized with ASL buffer in a bead beater (Mini-Beadbeater-8) twice for 
45s with one intervening minute on ice. Further extraction steps were performed 
using the QIAamp® DNA Stool Mini Kit (QIA-GEN) following the manufacturer‘s 
protocol (see chapter 11.1.). Quality of DNA extraction was verified by gel 
elektrophoresis in 1% agarose gel. Thereafter DNA was stored at -20°C until 
the analysis was conducted. 
 
8.4. Type strains  
Cloned sequences and type strains, which are known to be a part of the human 
gastrointestinal microbiota were set as standards in the real-time PCRs and 
were used to create a standard lane marker for DGGE analysis. For latter 
following type strains were used: Bacteroides thetaiotaomicron DSM 2079T, 
Enterococcus faecium DSM 20477T, Lactobacillus reuteri ATCC 55730T,  
Bifidobacterium longum ssp. longum DSM 20097T, Escherichia coli IMBH 
252/07 and clones CL16 and CC34. 
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8.5. Clone library   
The process of cloning in molecular biology refers to the creation of copies of a 
DNA fragment of interest. Figure 5 shows a schematic overview of the process.  
   
   
The amplified DNA fragment is inserted into a vector (p-GEM easy, Promega, 
Austria) containing an ampicillin resistance gene. Next, the vector with insert is 
inserted into competent E.coli, this is termed transformation. If a bacterial cell 
has incorporated the plasmid, it will grow on a LB plate containing ampicillin. 
With the help of blue-white screening bacteria with inserts can be detected. 
These bacteria can now be grown in large amounts and the target DNA is 
isolated again by PCR.  
The object of the clone library in this study was to design a standard lane 
marker for the DGGE analysis and to identify dominant members of the 
Clostridium Cluster XIVa. For these purposes a PCR was performed with 
primers 195-F [MEIER et al., 1999] and Ccocc-R [MATSUKI et al., 2004] and 
the amplified products were inserted into a p-GEM Easy Vector (Promega) 
Figure 5: Procedure of molecular cloning 
[BIOMINEWIKI, 2011] 
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following the instructions of the manufacturer (see also chapter 11.2.). Four 
LB/ampicillin/IPTG/X-Gal plates were prepared for each ligation reaction and 
one plate for determining transformation efficiency. 2x100 µl of each diluted 
transformation culture were plated and incubated at 37° over night. On the third 
day of the cloning procedure plates were screened for blue and white colonies. 
White colonies contained vectors and inserts, whereas blue colonies had no 
inserts. Then fifty clones were picked, transferred to clean Eppendorf tubes and 
amplified with Promega primers T7 and Sp6. The fragment length was checked 
on a 2% agarose gel. Finally, the clone inserts were sequenced (DNA 
confidence, Vienna) and corrected for primer and vector sequences 
(CodonCodeAligner). The taxonomical identification was performed with the 
online tools of the ribosomal database project (http://rdp.cme.msu.edu/). The 
clone library with the purpose of creating a standard lane marker for DGGE 
analysis of Clostridium cluster IV has previously been described [ZWIELEHNER 
et al., 2009]. 
 
8.6. Polymerase chain reaction (PCR)  
The polymerase chain reaction (PCR) is a molecular technique with the purpose 
of amplifying a specific region of a DNA strand (the DNA target). PCR makes it 
possible to produce thousands to millions of copies out of a single piece or a 
few copies of the target DNA. In contrast to cloning no bacteria are needed to 
amplify DNA in PCR. The PCR reaction requires following components: 
• A DNA template containing the target sequence  
• DNA polymerase: A heat resistant enzyme that can generate new strands of 
DNA complementary to the target region. The most commonly used DNA 
polymerase is Taq DNA polymerase, which was originates from the thermophilic 
bacterium Thermus aquaticus. Since DNA polymerases can only add new 
nucleotides to an existing strand of DNA, two primers are needed as starting 
points. 
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• Primers are short single-stranded oligonucleotides which are the reverse 
complement of a region of template or target DNA. Before using PCR it is 
necessary to know the exact sequences that lie on either side of both ends of 
the target region, to design two fitting primers for the PCR reaction.  
• Nucleotids (dNTPs) are single units of the bases adenine, thymine, guanine, 
and cytosine. They are essential to synthesize new DNA strands. 
• Buffer and MgCl2 are needed as polymerase cofactors as well as bovine 
serum albumin (BSA) in some cases. Distilled water is used to fill up to the 
required reaction volume. 
A PCR reaction is actually 
composed of more than 40 
cycles, with each cycle consisting 
of three recurring temperature 
steps (figure 6). During initial 
denaturation, the reaction mix is 
heated to a temperature of 
approximately 94-96° C and held 
for several minutes to denature 
the original DNA strands and 
activate the heat-stable 
polymerase. Then 20-40 cycles 
follow. During denaturation the 
reaction mixture is heated to 
approximately 95°C for 20-30 
seconds, which results in melting 
of the DNA template yielding single-stranded DNA molecules. The denaturation 
is followed by the annealing step, where the temperature is lowered to let the 
primers anneal to the complementary regions on the single stranded DNA 
template. The polymerase binds to the primers and synthesizes new DNA 
strands using dNTPs in elongation step at a temperature optimal for the 
polymerase. After the last cycle a final elongation step may be used to assure 
Figure 6: Polymerase chain reaction 
[VIERSTRAETE, 1999] 
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that any remaining single-stranded DNA is fully elongated. PCR reactions are 
exponential, therefore the amount of DNA target should be doubled in each 
PCR cycle under optimum conditions. 
Agarose gel electrophoresis is performed to check whether the amplified DNA 
fragment has the right fragment length. The determination of the size of PCR 
products is made with a special DNA ladder, which is comprised of DNA 
fragments of known size and is applied on the gel next to the PCR products. 
PCR experiments in this study were carried out in a Robocycler (Stratagene) 
amplifying 16S rRNA gene sequences from bacteria in stool samples, type 
strains and cloned sequences for DGGE analysis and to create a clone library 
using group and kingdom-specific primers (see Table 2). The 16S rRNA is a 
component of the 30S subunit of ribosomes in prokaryotes. The 16S ribosomal 
RNA gene is highly conserved between different species of archaea and 
bacteria, that is why it is commonly used for phylogenetic studies among 
prokaryotes.  
The PCR reaction mixture consisted of following components: 
• ready-to-use mastermix (Promega) containing 1,5mM MgCl2 
• 500nmol/L of both primers 
• 2µl template 
• For faecal samples, bovine serum albumin (Fermentas) was added with 
a final concentration of 400µg/ml 
 
8.7. PCR-DGGE fingerprinting 
Denaturating gradient gel electrophoresis is a form of electrophoresis that uses 
a chemical gradient to denature 16S rRNA gene fragments as they move 
across an polyacrylamide gel. The chemical denaturants used are formamide 
and urea. During DGGE PCR products are separated sequence-specifically on 
the basis of their melting behavior, which depends on the GC content of the 
fragments and length. PCR products of same length are separated according to 
their base sequence, by this means a separation with a difference of a single 
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nucleotide is possible. For the preceding PCR special primers are used 
containing a GC-clamp, which is an approximately 40 base pairs region 
consisting mainly of guanine and cytosine and prevents DNA fragments from 
melting completely. To identify the PCR products the resulting bands on the 
DGGE gel are compared with references lanes consisting of amplified DNA 
fragments of known bacteria. Some microorganism like lactobacilli, some fungi 
and Bacteroides thetaitaomicron produce several bands due to their multiple 
16S rRNA operons [HIPPE et al., 2011]. This results in a pattern of bands on 
the gel. An analysis of the bands can be carried out with a special software (Gel 
Compare II, Applied Maths NV, Belgium). DNA fragments can also be cut out 
and sequenced. 
PCR–DGGE was performed as previously described by Muyzer et al. [MUYZER 
et al., 1993]. Table 2 shows used primer pairs and annealing temperature for 
bacteria, Clostridium cluster IV and Clostridium cluster XIVa. 
 
Table 2: Primer pairs for PCR-DGGE fingerprinting of 16S rRNA coding regions 
 
PCR products had to be precipitated for the DGGE due to the fact that 100 µl is 
too large a reaction volume for the slots of the gradient gel. For the precipitation 
-20°C cold ethanol was added to the PCR product using ten times more ethanol 
than product. Then the ethanol-PCR product mix was incubated at -20°C 
overnight and after that centrifuged for 20 minutes. The supernatant was 
discarded and the precipitate was dried at 37°C for 24 hours. Finally it was 
resuspended with 15μl NFW + 5μl loading dye. For preparation of the gradient 
Target organism Primers Sequence (5' - 3')
Annealing 
temperature 
(°C) Reference
Bacteria 341-F-GC CCT ACG GGA GGC AGC AG 55 MUYZER et al, 1993
518-R ATT ACC GCG GCT GCT GG 55 NEEFS et al., 1991
Clostridium cluster IV sg-Clept-F-GC GCA CAA GCA GTG GAG T 55 MATSUKI et al., 2004
sg-Clept-R CTT CCT CCG TTT TGT CAA 55
Clostridium  cluster XIVa Ccocc-F-GC AAA TGA CGG TAC CTG ACT AA 50 MATSUKI et al., 2004
Ccocc-R CTT TGA GTT TCA TTC TTG CGA A 50
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gels a gradient mixer (Hoefer SG 30) and a peristaltic pump were used. After 
resuspension the precipitated DNA was injected into the slots of the gel using a 
Hamilton syringe. Run time and gradient varied according to species (table 3). 
Standard lane markers as described above were used on each gel to ensure 
reliable gel-to-gel comparison. Gels were stained with GelRed and 
photographed under ultraviolet light. The bandpattern was analysed using 
GelCompareII (see also chapter statistical analysis). 
 
 
 
 
8.8. Quantitative measurement – TaqMan-qPCR  
The quantitative real-time polymerase chain reaction (qPCR) is used for 
absolute or relative quantification of microbial DNA [HIPPE et al., 2011] or to be 
precise to amplify and simultaneously quantify the DNA target. In contrast to 
endpoint PCR, qPCR allows monitoring the amplification in real time. 
Sequence-specific DNA probes with fluorescent reporters (eg. TaqMan Probes) 
or non-specific fluorescent dyes intercalating with dsDNA (SybrGreen) are 
used. During qPCR the fluorescence emission is directly proportional to the 
quantity of PCR product. The CT-Value (cycle threshold value) indicates the 
cycle number at which the fluorescence signal exceeds the fluorescence 
threshold.  
TaqMan probes are oligonucleotides consisting of approximately 20-30 bases 
and anneal to an internal region of the PCR product. They are labeled with a 
fluorophore (reporter) on the 5‘end and a quencher on the 3‘ end. The quencher 
prevents emission of any fluorescence as long as quencher and reporter are in 
close proximity. When the DNA polymerase extends the primer and replicates 
Target Gradient Runtime (hours) Volt (V) Temperature (°C)
Bacteria 30-60% 9 130 60
Clostridium  cluster IV 30-50% 5 200 60
Clostridium  cluster XIVa 35-50% 7 200 60
Table 3: DGGE and gel settings of analyzed groups 
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the PCR product, the bound TaqMan Probe degrades due to the polymerase's 
exo-polymerase activity and the fluorophore is released. This ends the activity 
of the quencher and the reporter starts to emit fluorescence. 
In this study quantification of bacteria and bacterial subgroups was performed 
with qPCR using TaqMan probes. Analyses were performed in a Rotorgene 
3000 (Corbett Life Science). The primers and probes for detection were based 
on 16S rRNA gene sequences acquired from different references (see Table 4). 
Optimal annealing temperatures of primer pairs were ascertained as previously 
described by Lassl 2009 [LASSL, 2009]. 
 
Table 4: 16S rRNA gene-targeted group-speciﬁc primers used in this study 
 
The reaction mixture of 10µl was composed of 5µl Taq-Man SensiMix DNAKit 
(Quantance), 2 µl of sample DNA, 1µl of each primer and 1µl Taq-Man-probe. 
Primers and probes were diluted to a specific concentration with nuclease free 
Target Primer/probe Sequence Size
all Bacteria BAC-338-F ACT CCT ACG GGA GGC AG 468
BAC-805-R GAC TAC CAG GGT ATC TAA TCC
BAC-516-P (6-FAM)-TGC CAG CAG CCG
Bacteroides AllBac296f GAG AGG AAG GTC CCC CAC 106
AllBac412r CGC TAC TTG GCT GGT TCA G
AllBac375Bhqr (6-FAM)-CCA TTG ACC AAT ATT CC CAC TGC TGC CT-(BHQ-1)
Bifidobacteria Bif-F  GCG TGC TTA ACA CAT GCA AGT C 125
Bif-R   CAC CCG TTT CCA GGA GCT ATT
Bif-P   (FAM)- TCA CGC ATT ACT CAC CCG TTC GCC -(BHQ-1)
Clostridium cluster IV sg-Clept-F GCA CAA GCA GTG GAG T 239
sg-Clept-R  CTT CCT CCG TTT TGT CAA
Clept-P  (FAM)-AGG GTT GCG CTC GTT-(BHQ-1)
Clostridium  cluster XIVa 195-F  GCA GTG GGG AAT ATT GCA 538
Ccocc-R  CTT TGA GTT TCA TTC TTG CGA A
Ccocc-P  (6-FAM)-AAA TGA CGG TAC CTG ACT AA-(BHQ-1)
Clostridium difficile Cdiff-F TTG AGC GAT TTA CTT CGG TAA AGA 151
Cdiff-R TGT ACT GGC TCA CCT TTG ATA TTCA
Cdiff-P (6-FAM)-CCA CGC GTT ACT CAC CCG TCC G-(BHQ-1)
*modified forward primer
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water (see table 5). Samples were analyzed in duplicates and the mean value 
was used for calculations. As seen in table 5 amplification programs differed 
depending on primers and probes. To determine the sensitivity of the real-time 
TaqMan assay and to construct standard curves, serial 10-fold dilutions of 
standards were subjected to PCR. Standards used included Bacteroides 
thetaiotaomicronT, Bifidobacterium longum ssp. longumT and Clostridium 
difficileT, clones CL 16 (Clostridium leptum 16) and B 34 plasmid DNA 
(Clostridium coccoides 34). For universal bacterial primers a known faecal 
sample was set as standard.  
 
Table 5: Concentration of primers, PCR programs and standards  
DNA concentrations of Bacteroides thetaiotaomicronT, Bifidobacterium longum 
ssp. longumT and Clostridium difficileT were determined using a nanodrop 
spectrophotometer. The number of DNA copies per microliter was then 
calculated by use of the mean G and C content of each strain. Clones CL16 and 
plasmid DNA B34 were quantified by determination of colony forming units 
Target Standard Primer/probe Concentration Hold
Number 
of cycles
all Bacteria standard mix BAC-338-F 10pmol/µl 95° 10min 40
BAC-805-R 10pmol/µl
BAC-516-P 2pmol/µl
Bacteroides RK Bacteroides thetaiotaomicron AllBac296f 3pmol/µl 95° 10min 40
(DSM 2079) AllBac412r 3pmol/µl
AllBac375Bhqr 1pmol/µl
Bifidobacteria RK Bifidobact. longum sp. longum Bif-F  3pmol/µl 95° 10min 40
DSM 20219 Bif-R   3pmol/µl
Bif-P   3pmol/µl
Clostridium  cluster IV Clone 16 (C.lept .) sg-Clept-F 4pmol/µl 95° 10min 40
sg-Clept-R  4pmol/µl
Clept-P  4pmol/µl
Clostridium cluster XIVa B 34 plasmid DNA (C.cocc .) 195-F  5pmol/µl 95° 15min 40
Ccocc-R  5pmol/µl
Ccocc-P  1,5pmol/µl
Clostridium difficile 30 19 68 DNA (C.diff ) Cdiff-F 10pmol/µl 95° 10min 40
Cdiff-R 10pmol/µl
Cdiff-P 2pmol/µl
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(CFU) per µl. Absolute quantification was calculated by comparing Ct-values of 
test samples to standard curves. For comparison of different runs, a control 
sample was used in each run. Relative quantification of bacterial subgroups 
was determined by comparison of total rRNA gene copies amplified with 
universal bacterial primers BAC-338-F and BAC-805-R. 
 
8.9. High throughput sequencing 
Pyrosequencing is an enzyme-catalysed cascade with a light-reaction at its end 
indicating which nucleotide has currently been incorporated. The method relies 
on detecting the activity of DNA polymerase while synthesizing the 
complementary strand of the target DNA. Solutions of A, C, G and T nucleotides 
are successively added and removed to the immobile template DNA in the 
reaction. When the complementary nucleotide solution anneals to the first 
unpaired base, a chemiluminescent signal is emitted. The sequence of the 
target DNA can be determined by detecting these light signals. 
454 life sciences has developed a whole genome high-throughput-sequencing 
technology by integrating pyrosequencing with their PicoTiterPlate (PTP) 
platform. Simultanous amplification of approximately 300,000 PCR templates is 
possible [LEAMON et al, 2003]. In the beginning of the 454 sequencing process 
the DNA template is nebulized into double stranded fragments sized between 
300 and 800 basepairs. Then, DNA fragments are ligated to two different 
oligonucleotide adapters (A and B), which serve as binding sites for primers. 
DNA fragments are now denaturated and fixed to microscopic beads. Since 
there is a surplus of beads, statistically just one DNA fragment binds to one 
bead. After adding into a water-in-oil emulsion, little reaction volumina called 
microcontainer emerge, each containing one bead and one ssDNA template. 
The DNA within the microcontainers is then amplified using emulsion PCR. 
Each DNA-bound bead is placed into a well on a PicoTiterPlate. A DNA bead 
incubation mix (with DNA polymerase) and an enzyme mix (with sulfurylase and 
luciferase) is added and the PicoTiterPlate is then placed in to the GS FLX 
system for sequencing. Pyrosequencing starts and light signals are detected 
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with a CCD camera. A 10-hour run of sequencing results in about 400,000 
reads of 250–450 bp in length. An average quality score of greater than 99.5% 
accuracy rate is reached [DROEGE AND HILL, 2008]. 
High throughput sequencing was performed with four samples of P09 and P11, 
before and after chemotherapy. Samples were amplified with primer pair 525F 
(5‘-TCAGCAGCCGCGGTAATAC -3‘) and 926R (5‘-
TCCGTCAATTCCTTTGAGTTT -3‘) using a high-fidelity DNA polymerase 
(Phusion®, Finnzymes, Thermo Fisher Scientific). After 454 barcode 
sequencing (submission to AGOWA, Berlin, Germany) a total of 113000 reads 
resulted. Sequences were trimmed and aligned using the online tools of the 
pyro pipeline of the ribosomal database project (http://rdp.cme.msu.edu/). 
Sequences shorter than 151 bp were discarded, thus we had 3886 to 6811 
sequences per sample of 366 to 368 bp. The Peptostreptococcaceae were 
analyzed in more detail. A phylogenetic tree was constructed by grouping of 
identical sequences. All analyses were performed with the ribosomal database 
project pyro pipeline (http://rdp.cme.msu.edu/). 
 
8.10. Statistical analysis  
Statistical evaluation of relative and absolute abundances of total bacteria and 
bacterial subgroups were performed using the OriginPro Version 8 (OriginLab, 
Northampton, MA). Here, differences between the two test groups 
(chemotherapy patients and healthy controls) and changes between all sample 
points within the groups were compared. The nonparametric Mann-Whitney U 
test and the two sample t-test were applied for comparisons between two 
groups of independent ordinal and interval values. By this means absolute 
numbers of all bacteria and absolute and relative numbers of subgroups in 
oncology patients and healthy individuals were compared. Related data within 
the groups were analysed using the paired sampled t-test and nonparametric 
Wilcoxon signed rank test. P values <0.05 were considered statistically 
significant.        
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QPCR results were plotted in heatmaps to show the decline of bacteria in T1, 
the time point immediately after chemotherapy. Heatmaps are graphical two 
dimensional tables were the values are represented as boxes of different 
colorshades. In this study values for heatmaps have been z-scored for 
presentation clarity. Z scores indicate how many standard deviations a value 
differs from the mean. Z-scores are calculated by subtracting the mean value 
from the single values and dividing that result by the standard deviation of all of 
the measured values, according to the formula [CHEADLE et al, 2003] 
Z score = (absolute number of bacteriaG – mean 
numberG1…Gn)/SDG1…Gn  
PCR-DGGE fingerprint analysis and applied principal components analysis 
(PCA) were performed using GelComparII (www.applied-maths.com). PCA 
extracts underlying components of samples according to their variance. 
Shannon diversity index was calculated as previously described by Zwielehner 
[ZWIELEHNER et al., 2009]. Shannon index is defined as H = -Σ pi ln pi, where 
pi is the proportional abundance of species i. The higher the Shannon index, the 
higher the diversity.  
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9. RESULTS 
9.1. Dietary aspects and life-style 
All study participants had to answer a food frequency questionnaire to assess 
their dietary habits. There were no significant differences in patients and healthy 
controls regarding their consumption of vegetables, grains and milk products. 
Patients undergoing chemotherapeutical treatment showed a lower intake of 
fruits, alcohol and whole grain products. Exercise levels in both groups were 
comparable. 
 
9.2. TaqMan-quantification 
Absolute numbers of bacteria and relative percentages of bacterial subgroups 
were analysed with TaqMan qPCR to investigate the influence of 
chemotherapeutical treatment with or without antibiotics on the human GI 
microbiota. 
 
9.2.1. Absolute quantification of total bacteria and bacterial subgroups 
Table 6 and 7 show absolute numbers of total bacteria and bacterial subgroups 
related to 2µl faeces extract of all study participants at the respective sampling 
times.  
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Table 6: Absolute numbers of total bacteria and bacterial subgroups in healthy 
controls analyzed by TaqMan-qPCR related to 10ng DNA 
 
 
Controls All bacteria Bacteroides Bifidobacteria C. cluster IV C.  cluster XIVa C. difficile
C01/1 437293.31 61137.23 244.85 133999.13 77472.39 0.00
C01/2 840409.88 53903.97 465.70 326262.04 231671.36 0.00
C01/3 1291348.28 124235.17 640.82 552740.21 396257.81 0.00
C02/1 856579.44 207233.10 0.24 135967.80 223387.78 0.00
C02/2 1280565.30 321264.60 1.19 171567.81 293190.19 0.00
C02/3 249524.26 63623.44 0.74 32472.41 75892.72 0.00
C03/1 751607.10 557747.57 991.00 111468.88 57415.28 0.00
C03/2 2668163.18 514696.31 2408.65 379907.50 367217.63 0.00
C03/3 3375548.55 186482.71 12636.00 548049.57 678856.47 0.00
C04/1 722947.60 195171.86 330.61 232319.29 125153.21 0.00
C04/2 1011436.68 255228.10 221.90 341438.29 171981.86 0.00
C04/3 2672234.13 339007.54 180.30 832030.13 692249.05 0.00
C04/4 2922631.37 352989.37 156.28 677275.84 505613.90 0.00
C05/1 1891206.07 727639.13 645.83 192574.41 262543.67 0.00
C05/2 2065267.30 671772.98 1507.87 210675.60 262463.98 0.00
C05/3 1733796.13 407584.71 443.34 214689.01 315715.33 0.00
C06/1 1570219.06 340733.04 445.59 390508.84 267016.08 0.00
C06/2 1072172.78 197189.12 120.55 251854.25 195722.06 0.00
C06/3 620482.19 152876.33 11.53 127675.45 117185.34 0.00
C07/1 357716.16 52897.34 84.70 112096.96 49725.20 0.00
C07/2 658745.28 71243.97 339.56 244238.66 95599.67 0.00
C07/3 767529.41 77325.31 314.44 283491.62 106300.82 0.00
C08 67127580.45 21630083.97 1104596.65 3016391.93 22372916.47 0.00
C09 126948085.08 19212984.02 2462247.54 9444500.94 68718443.26 0.00
C10 65278056.00 25196457.64 472238.95 1610808.79 14988708.20 0.00
C11 22910236.96 3611549.33 121147.51 750523.91 6857928.70 0.00
C12 47074467.77 18138079.80 353519.38 1308964.14 12538810.79 0.00
C13 286856946.54 16354683.44 372591.26 43891468.17 192415995.00 0.00
C14 58912801.05 10278138.84 527253.76 8869928.30 37824150.42 0.00
C15 137945616.44 15770084.32 510575.47 34278520.13 5002288.46 0.00
C16 30738626.46 10320149.60 576296.72 2839348.81 3367532.31 1807.64
MW 28180962.59 4724006.25 210408.35 3629476.09 11924367.92 78.59
STAB 60220057.59 7858906.72 492707.95 9807799.56 36394525.65 376.92
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Table 7A: Absolute numbers of total bacteria and bacterial subgroups in the 
oncology patients analyzed by TaqMan-qPCR related to 10ng DNA, P01-P10 
Patients All bacteria Bacteroides Bifidobacteria C. cluster IV C.  cluster XIVa C. difficile
P01/1 1798805.94 686436.18 22965.45 431283.01 179653.46 0.00
P01/2 372479.33 214081.92 4558.69 66859.19 17518.96 0.00
P01/3 1183463.77 453079.56 30777.49 349670.05 81729.38 0.00
P01/4 4900917.36 1757221.14 69416.26 894221.86 492005.88 0.00
P02/1 20212193.78 5354904.16 25.84 1727067.70 8456716.97 0.00
P02/2 23903696.36 4005111.16 366.48 1926246.84 6273075.75 0.00
P02/3 3129907.77 1537813.68 65.15 899451.34 202334.40 0.00
P02/4 42134076.47 8601362.67 266.24 6391142.51 11186629.09 0.00
P03/1 5252430.48 330458.04 303812.95 1584639.87 703331.31 0.00
P03/2 32539656.72 7049121.86 1322331.64 11554656.05 10912078.21 0.00
P03/3 8776038.82 1914216.02 68520.97 1613986.64 3585565.52 0.00
P03/4 34133421.73 5633416.81 368271.38 6935425.53 17973732.55 0.00
P04/1 10176085.75 3675199.65 123237.25 2790373.95 1828490.92 0.00
P04/2 2041417.98 124427.95 6748.31 1044114.49 456546.61 0.00
P04/3 9397403.84 2436596.74 150717.25 2484676.03 1113862.60 0.00
P04/4 17611326.10 3143896.40 388478.41 5200829.47 1762498.85 0.00
P05/1 58606024.90 7574676.76 1485218.67 8089718.24 10498104.44 0.00
P05/2 77914671.15 9930958.08 4295028.01 24053291.85 25121947.29 0.00
P05/3 47867203.61 10669686.99 2232338.50 8288562.23 21327802.26 0.00
P05/4 45546066.19 8990544.45 1150309.59 11197726.83 23100668.54 0.00
P06/1 4254777.75 1117961.90 150748.62 648065.08 1921015.97 0.00
P06/2 19663552.55 4064824.71 143528.56 1769516.54 4984825.07 0.00
P06/3 5817626.36 1692997.14 126902.02 1911000.59 1832499.43 0.00
P06/4 11491330.22 2619686.08 354166.89 1450849.53 3690397.55 0.00
P07/1 32882071.40 13715080.97 897.46 3410583.24 7731920.78 0.00
P07/2 14010666.45 2027428.84 1032.00 2671080.63 1991983.19 0.00
P07/3 31475072.44 16519292.63 823.50 1586561.05 13562.81 0.00
P07/4 210972.37 82379.99 34.45 55314.07 9572.75 0.00
P08/1 20526835.88 5611144.84 718.75 1247117.30 7680688.02 0.00
P08/2 44425634.50 16318239.73 895.78 3476321.68 15493685.21 0.00
P08/3 25709141.44 11964895.51 718.60 2268109.88 5119868.83 0.00
P08/4 4789406.38 1833583.83 50.22 255512.39 404272.01 0.00
P09/1 60928403.72 19783140.36 349975.84 6483641.99 5835644.77 6882.51
P09/2 79557247.54 24331906.09 426303.13 7125594.64 6230655.43 3410.13
P09/3 18692507.80 7732250.88 2051.63 1534255.90 6614636.98 228486.37
P09/4 22422312.29 7987608.92 13249.55 1508579.53 2774425.14 90328.31
P10/1 13477917.70 2837015.05 73.34 1122511.68 1498517.07 0.00
P10/2 18520677.78 2213914.71 15.13 830143.08 993439.98 0.00
P10/3 52591368.06 5899979.48 3869.15 2670649.71 4623410.70 0.00
P10/4 21962667.14 5147834.94 1465.47 1149697.73 2797644.59 0.00
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Table 8B: Absolute numbers of total bacteria and bacterial subgroups in the 
oncology patients analyzed by TaqMan-qPCR related to 10ng DNA, P11-P17 
 
Patients All bacteria Bacteroides Bifidobacteria C. cluster IV C.  cluster XIVa C. difficile
P11/1 44187524.40 6037882.96 441875.24 2509998.68 2374357.37 0.00
P11/2 9505774.72 865600.46 95057.75 1175348.89 2030535.80 0.00
P11/3 4652268.06 1640708.80 0.05 180029.67 397823.15 181438.45
P11/4 30489412.48 5277219.74 0.29 32637.34 292051.98 243915.30
P12/1 1101929.58 353588.40 1.37 111339.84 126430.54 0.00
P12/2 6715972.20 1220407.85 4.04 681879.34 730713.08 0.00
P12/3 2775027.99 721257.99 173.18 286183.85 509768.55 0.00
P13/1 1417002.07 236089.42 605.15 238326.79 210343.70 0.00
P13/2 1743935.23 229234.11 192.82 380815.57 219777.32 0.00
P13/3 9419678.45 1437380.19 1674.77 1821573.55 1187587.57 0.00
P13/4 2220094.29 214693.75 1193.98 383891.97 290244.10 3.95
P14/1 2812806.45 339245.97 51.39 619589.76 388784.99 82.69
P14/2 1898857.79 318576.67 226.39 440094.63 234728.66 0.00
P14/3 216491.56 100645.68 332.65 61728.96 31497.30 0.00
P15/1 819799.59 290536.62 344.12 148236.56 142420.79 0.00
P15/2 515193.86 148824.80 902.84 116214.55 84706.60 1.00
P15/3 809754.51 384999.39 5732.25 130018.93 130299.63 0.00
P15/4 1534925.19 486963.46 1752.75 175493.57 195136.85 0.00
P16/1 1378646.12 519302.17 19.94 209558.66 182349.69 6.97
P16/2 1343463.89 445758.10 7.04 200913.16 147572.01 0.00
P16/3 1152274.79 309769.22 99.83 170553.86 150962.71 0.00
P16/4 1229934.96 302951.10 48.50 243413.25 165421.24 0.00
P17/1 1221647.49 231511.65 2.50 151162.87 178143.59 0.00
P17/2 661624.52 71960.51 5.85 92751.67 128249.19 0.00
P17/3 2197256.20 267220.69 80.13 254390.04 369677.36 0.00
P17/4 1698079.84 315570.29 64.88 196263.35 248026.25 0.00
MW P01-17 16433740.21 3944731.47 214415.52 2298658.47 3616129.84 26948.42
STAB P01-17 19782724.05 5196061.66 642056.52 3798481.66 5779273.42 70054.14
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As shown in figure 7, patients receiving chemotherapy (± antibiotics) harbored 
significantly less bacteria (p< 0.05) than healthy controls. Considerable 
differences were also shown among absolute numbers of microbiota of several 
sampling times: Absolute numbers of bacteria in different points in time of 
healthy controls are following a lognormal distribution in contrast to the shifts in 
oncology patients. Faecal microbiota of patients with cycles of chemotherapy 
decreased significantly more between two time points (p=0,027) than healthy 
controls. 
As seen in figure 7 absolute numbers of bacteria (p = 0.037) were significantly 
lower directly after cycles of chemotherapy (T1). There was also a significant 
decrease in the bacterial subgroups of Bacteroides (p=0.044), bifidobacteria 
(p=0.034) and Clostridium cluster IV (p=0.049). Clostridium cluster XIVa was 
Figure 7: Comparison of absolute numbers of bacteria analyzed by 
TaqMan-qPCR in oncology patients and healthy controls and 
different time points of cycles of chemotherapy in copies/10ng DNA  
P, oncology patients; C, healthy controls; To, before chemotherapy; 
T1, 1-2d after chemotherapy, T2 >2d after chemotherapy 
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effected too, but not significantly. Figure 8 illustrates that all patients with fever 
(P01/4, P08/2, P09/2) showed an increase of total fecal microbiota. Sample P07 
showed at time point 4 a sharp decline affecting all bacteria and bacterial 
subgroups after a blood stem cell transplantation. After the end of 
chemotherapeutic treatment the abundance of fecal microbiota went back to 
normal levels within a few days. Six patients even showed a ―rebound effect‖ 
within the recovery phase with a short lived increase of total bacteria to higher 
amounts than in the beginning. 
Figure 8: Absolute numbers of bacteria of the study population analyzed 
by TaqMan-qPCR related to 10ng DNA; T1, 1-2d after chemotherapy 
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9.2.2. Relative quantification of bacterial subgroups 
Table 8 and figure 9 show the quantification of bacterial subgroups as 
percentage of total bacterial DNA at the different points in time. Chemotherapy 
patients had a mean percentage of 26 ± 12% Bacteroides, while healthy 
controls harbored 22 ± 14%. Patients harbored in average 0.8 ± 1.4 % 
bifidobacteria and controls 0.3 ± 0.6 %. In patients the mean proportion of 
Clostridium cluster IV and Clostridium cluster XIVa was 16 ± 9 % and 19 ± 12 
%, while controls harbored on average 20 ± 12 % and 24 ± 15 %. 
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Table 9:  Relative numbers of bacterial subgroups 
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Bacteroides
Bifidobacteria
C.Cl. IV
C.Cl. XIVa
C. difficile
unidentified
As illustrated in figure 10 patients under chemotherapeutical administration 
showed significantly less Clostridium cluster XIVa (p = 0,021) than healthy 
individuals. The other observed subgroups showed no statistically significant 
difference between oncology patients and healthy subjects. 
 
Figure 10 shows that the mean percentage of Clostridium cluster XIVa 
decreased after bouts of chemotherapy. Before chemotherapy the mean 
proportion of Clostridium cluster XIVa was 22 ± 13% compared to 19 ± 12% 
after chemotherapeutical treatments. 
 
 
 
Figure 9: Percentages of bacterial subgroups in relation to analyzed bacteria 
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Oncology patients harbored 26 ± 11%, 1.4 ± 2% and 16 ± 9% of Bacteroides, 
bifidobacteria and Clostridium cluster IV before chemotherapy and 28 ± 14%, 
0.5 ± 1.2% and 18 ± 12 % after cycles of chemotherapy. The differences were 
not significant. 
We tried to find out whether a chemotherapeutic and/or antibiotic disruption of 
the microbiota favors the growth of pathogens by investigating all samples for 
pathogenic Clostridium difficile. In three out of seventeen patients (18%) 
receiving chemotherapeutic ± antibiotic treatment Clostridium difficile was found 
(P09, P11, P14), especially subject P09 and P11 harbored considerable 
numbers. Patient P09 harbored C. difficile in all four samples investigated. The 
mean percentage of C. difficile in this subject over all four points in time was 0.4 
± 0.7%, the highest number was recorded at time point T1 (P09/3), which was 
taken immediately after a bout of chemotherapy and a treatment with 
antibiotics. Also in patient 11 and patient 14 a colonization with C. difficile was 
Figure 10: Relative abundances of Clostridium Cluster XIVa in 
oncology patients compared to healthy controls and before and 
after chemotherapeutic cycles as percentage of total bacterial 
DNA. P, oncology patients; C, healthy controls; To, before 
chemotherapy; T1, 1-2d after chemotherapy 
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found after chemotherapeutic intervention. (P11: 3,90%, P14: 0,003% of all 
analzyed bacteria). Sample P09/1, P09/3, P11/1 and P11/3 at time points T0 
and T1 of patients P9 and P11 were further analyzed by 454 sequencing.  
Small amounts of C. difficile were also found in three other patients, but they 
were below the detection limit. Except for C16 with a proportion of 0,006% of all 
bacteria, healthy controls didn‘t harbor C. difficile. 
 
9.3. DGGE bandpattern analysis 
DGGE fingerprinting analyses of total bacteria, Clostridium cluster IV and 
Clostridium cluster XIVa point out a high diversity of fecal microbiota between 
individuals. Table 9 shows the mean number of bands per oncology patient and 
healthy control. 
 
Table 10: Mean number of bands in study population analyzed with PCR-
DGGE and GelCompareII 
The number of Clostridium cluster IV bands before chemotherapy (T0) was 14 ± 
7, whilst immediately after chemotherapy (T1) the number declined to 10 ± 6. At 
time point T2 meaning a few days after chemotherapy the number of bands 
increased to 15 ± 6. The dataset was subjected to principal component analysis 
(PCA), which extracts underlying components of samples according to their 
variance.  
Figure 11 A displays the bacterial fingerprints of sample P01 over the course of 
time. Figure 11 B illustrates the Shannon diversity index of Clostridium cluster 
IV fingerprints, indicating characteristics before and after chemotherapy in 
oncology patients compared with the healthy control group. DGGE fingerprints 
Oncology patients Healthy controls
Bacterial group
Mean number 
of bands Bacterial group
Mean number 
of bands
All bacteria 19 ± 4 All bacteria 19 ± 3.5
Clostridium cluster IV 14 ± 6 Clostridium cluster IV 12 ± 5
Clostridium  cluster XIVa 14.9 ± 7 Clostridium  cluster XIVa 18.9 ± 7
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of individuals show smaller variability in PCA analysis after chemotherapy (T1 
and T2) compared to healthy controls (C) and patients before onset of treatment 
(T0). PCA resulted in distinctive clustering of band patterns before and after 
chemotherapy [ZWIELEHNER, 2010]. 
 
9.4. High throughput sequencing 
As shown in figure 12 454 sequencing showed a severe decrease of 
Faecalibacterium spp. as well as lactobacilli, Veillonella spp., bifidobacteria (in 
P09) and E.coli / Shigella immediately after chemotherapy in oncology patients 
P09 and P11.  
P09 additionally received concomitant antibiotics. Especially Faecalibacterium 
spp. was strongly reduced from 9.5% and 8.3% to 0.07% and 0.00%, 
Figure 11A: Changes of PCR-DGGE fingerprinting of 16S rRNA coding 
regions of dominant bacteria after chemotherapeutic treatment. Arrows 
indicate nearly disappearing or stronger bands. A, B, C and D, samples of 
ON001 after chemotherapy; E, healthy control; SL, standard lane 
11B: Shannon diversity index of Clostridium cluster IV fingerprinting and PCA 
[ZWIELEHNER, 2010] 
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respectively. In contrast 
Enterococcus faecium increased 
after chemotherapy in both 
individuals. Furthermore, a strong 
increase in sequences within the 
Peptostreptococcaceae towards 
sequences 98.9–100% similar to 
C.difficileT occurred: Clostridium 
bartletti related sequences (98.1–
100% similarity) were only detected 
in fecal samples taken before 
chemotherapy (T0). Immediately 
after chemotherapy (T1), 63 
sequences 98.9–100% similar to 
C.difficile appeared in samples P11 
and P09, they are shown as 
‗unclassified Peptostrepto-
coccaceae' in figure 12. 
Further less abundant sequences 
appeared that were not detected 
before treatment: Eggerthella, 
Megasphaera, Parvimonas, 
Anaerostipes, Eubacterium, 
Anaerococcus, Methylobacterium, 
Holdemania, Turicibacter, 
Akkermansia, Sutterella (in P09), 
Sphingomonas, Anaerotruncus, 
Coprococcus, Streptococcus and 
Dorea. The number of Blautia 
species in C. cluster XIVa remained constant before and after 
chemotherapeutic treatment.  
Figure 12: Heatmap showing 
abundances within the 454 sequencing 
dataset on the genus level. Species with 
abundance <0.01% of all sequences are 
not shown. [ZWIELEHNER et al., 2011] 
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10. DISCUSSION 
 
Chemotherapeutic regimen and administration of antibiotics cause severe side 
effects in oncology patients, which often result in life threatening complications 
and increase the cost of health services. Diarrhea and constipation are common 
harmful secondary effects, furthermore mucositis is a major problem induced by 
the cytotoxic effects of cancer therapy and radiotherapy [GIBSON et al., 2006; 
STRINGER et al., 2007]. Chemotherapeutic and antibiotic use increases the 
risk of infection and overgrowth with potential pathogenic species such as C. 
difficile by interfering with the composition of the native gut microbiota [VAN 
VLIET et al. 2009]. 
 
In this study we investigated how the gastrointestinal microbiota of oncology 
patients was affected during cycles of chemotherapy (± antibiotic 
administration). We evaluated the shifts of the microbial ecosystem following 
chemotherapy and antiobiotic treatment and tried to assess if the microbiota 
was able to recover fully after therapy. Special focus was on the abundance on 
potential pathogenic C. difficile. 
 
10.1. Material and Methods 
The majority of the study population had a longer history of different 
chemotherapy treatment regimes over the course of several years. Only two 
study participants (P01 and P08) had never received any cancer therapy 
before. The results in this study illustrate changes due to a single bout of 
chemotherapy, but the observed shifts in microbiota are likely to be affected by 
previous cycles.  For this reason, the results cannot rule out, that observed 
changes are influenced by previous therapies. For example, cancer patients 
showed a significantly lower abundance of total bacteria numbers, which could 
be the result of previous treatments. 
Furthermore the treatments were different and they suffered from a variety of 
malignancies. Six oncology patients also received antibiotics, which poses the 
risk to falsely interpret the effects of antibiotic treatment as effects of 
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chemotherapy. However, they showed a similar response to chemotherapy like 
the rest of the study group, so it can be hypothesized that the disbalance of the 
gut microbiota was caused by the chemotherapeutic intervention itself. Three 
patients (P12, P13 and P17) suffered from different kinds of cancer of the 
intestine. A recent work observed a composition change in the microbiota of 
colon cancer patients [SOBHANI et al., 2011]. This fact should be considered in 
future investigations. 
 
The human gastrointestinal tract is colonized by autochthonous microbiota 
[WANG et al., 2003]. The bacterial communities found at different sites of the 
intestine vary significantly, especially when comparing samples of upper GI-
tract with samples from the lower intestine [PASTER et al., 2001; PEI et al., 
2004). It was postulated in previous works that the fecal microbiota consists of 
shed mucosal bacteria and a separate nonadherent luminal population 
[ECKBURG et al., 2005]. While further studies suggested that fecal samples do 
not necessarily represent the microbial populations in other parts of the 
gastrointestinal tract [WANG et al., 2003; ZOETENDAL et al., 2002], a recent 
work of Van der Waaij et al. showed that the composition of the bacterial 
microbiota present in the feces was similar to that at the mucus layer of the 
terminal ileum and colon regions. Furthermore they did not observe direct 
contact between epithelial cells and bacteria, which suggested that there is no 
specific mucus-adherent microbiota [VAN DER WAAIJ et al., 2005]. 
Due to the inaccessibility of human intestinal tract we chose fecal samples for 
our investigations, even though the fecal microbiota might differ from the 
adherent microbiota, which can only be assessed by colonic biopsies. 
Compared to biopsies, fecal samples are easy to collect, less invasive and do 
reflect changes in microbial population composition of the gut [TURRONI et al., 
2008].  
Stool samples were frozen prior to DNA extraction, which is widely used in 
metagenomic studies. However, a recent work observed that freezing may 
affect the community composition. In this study the Firmicutes to Bacteroidetes 
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16S rRNA gene ratio was significantly higher in stool samples that had been 
frozen compared to identical samples that had not been [BAHL et al., 2012].  
 
Previous works have done research on the effects of chemotherapeutic 
treatment ± antibiotic use on the intestinal microbiota [VAN DER WAAIJ, 1984; 
STRINGER et al., 2008]. The majority of these earlier studies applied culture 
dependent methods, which were common practice before the development of 
molecular detection methods. Fecal microbiota was monitored and identified 
mainly by cultivation on selective growth medium and other culture dependent 
methods, which are limited in assessing entire microbial populations because a 
large fraction of gastrointestinal bacteria has never been cultured and escapes 
detection. The implementation of culture-independent approaches to study the 
microbial gut composition has made it possible to assess the host's intestinal 
microbiota independent of culturing techniques and thus, broadened our 
knowledge of the diversity of species present in the gastrointestinal microbiota 
[MUYZER et al. 1993, MUYZER, 1999]. The investigation of rRNA as a 
molecular clock has become established for phylogeny and classification of 
microbes and the 16SrRNA gene harbours sufficient variable region of 
identification and differentiation of specific species [ZOETENDAL et al., 2006].  
 
In this study a combination of 16S rRNA based molecular methods was 
applied. Real time quantitative PCR was used for relative and absolute 
quantification of all bacteria,  Bacteroides, bifidobacteria, Clostridium cluster IV, 
Clostridium cluster XIVa and Clostridium difficile. Although PCR is a highly 
sensitive and specific technique, all PCR-based methods are affected by bias, 
induced among others by rehybridisation of PCR products or different primer 
binding energy. To ensure an accurate and successful qPCR assay, in this work 
specificity of all PCR reactions was confirmed using target and non-target DNA 
and sensitivity of all PCR reactions was determined with 10 fold dilutions of 
standard curve DNA. Furthermore, clone libraries were constructed and the 
obtained sequences allowed an estimate of the primer specificity. 
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Species richness and diversity was assessed using PCR-DGGE fingerprinting. 
Each lane of the PCR-DGGE gel displays a microbial fingerprint of a stool 
sample; within a lane each band usually represent one bacterial species, 
although it also happens that different species are represented by the same 
band [VAN VLIET et al., 2009] or one bacterial strain form several bands. Latter 
is associated with species including multiple 16S rRNA operons, e.g. E.coli. 
Limitations of DGGE technique in analysis microbial communities have been 
previously described [MUYZER et. al, 1998].  
 
DNA sequencing is used for determining the DNA sequence meaning the 
order of the nucleotides bases (A, G, C, T) in a DNA molecule. Demand for 
DNA sequence information has never been greater, since earlier commonly 
used Sanger technology is too costly, time consuming, and labor intensive to 
meet this ongoing demand [METZKER, 2005]. There is a coming of several new 
high-throughput technologies, all having in common the demand for low cost 
sequencing with parallelization of the sequencing process in order to produce 
thousands or millions of sequences at once. Pyrosequencing itself is no high 
throughput sequencing technology but provides the basis for 454 sequencing. 
In contrast to Sanger sequencing which relies on chain termination with 
dideoxynucleotides pyrosequencing is based on the detection of pyrophosphate 
release during DNA synthesis. High-throughput molecular technologies can 
profile microbial populations at high resolution even in complex environments 
like the gastrointestinal tract. To gain a decent accuracy it is important to 
minimize the amplification bias and to select sequencing primers and variable 
16S rRNA gene regions with great care [CLAESSON et al., 2010]. 
 
10.2. Results 
The results show significant effects of chemotherapy and antibiotic treatment on 
the intestinal microbiota. The absolute abundance of bacteria was significantly 
lower in patients under chemotherapeutic administration than in healthy 
controls, which is in agreement with previous studies [VAN VLIET et al., 2009]. 
The numbers of bacterial subgroups changed together with total bacteria both in 
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patients with and without antibiotics. To consider the high individual variations 
both test and healthy control group were observed over a course of time, thus 
significant differences were also shown among absolute numbers of microbiota 
of several sampling times: the total bacteria load in different points of time in 
healthy controls followed a lognormal distribution in contrast to the shifts in 
oncology patients. Fecal microbiota of patients with cycles of chemotherapy 
decreased significantly more between two time points than healthy controls. 
Furthermore, numbers of total bacteria, bifidobacteria, Bacteroides, and 
Clostridium cluster IV were significantly lower directly after cycles of 
chemotherapy (T1). In contrast, increased relative counts of Bacteroides spp. 
could be observed in patients undergoing chemotherapeutical treatment, which 
is in agreement with previous results [NYHLEN et al., 2002]. Nyhlen et al. also 
reported increased counts of yeasts in patients, but yeasts were not subject of 
this study. 
 
After the end of chemotherapeutic treatment the abundance of fecal microbiota 
went back to normal levels within a few days. Six patients even showed a 
―rebound effect‖ within the recovery phase with a short lived increase of total 
bacteria to higher amounts than in the beginning. All patients with fever (P01/4, 
P08/2, P09/2) showed an increase of total fecal microbiota. Fever in 
immunocompromised patients is the principal and sometimes the only 
manifestation of serious infection [PIZZO, 1999], which might be due to 
increased numbers of pathogenic species in the gut or an overall bacteria 
overgrowth. 
 
Species richness decreased immediately after a chemotherapeutic cycle. 
Especially Clostridium cluster IV was affected with a number of 14±6.7 different 
bands before chemotherapy (T0) decreasing to 10±6.6 bands shortly after (T1). 
Even after recovering to 15±6.6 bands later, PCA observed a persisting 
different composition of Clostridium cluster IV species. 
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PCR DGGE analysis revealed that no significant differences existed in 
fingerprints of all bacteria in patients with or without antibiotic treatment. 
Clostridium cluster XIVa showed a decreased number of bands, but differences 
were not significant. Results indicate that the observed changes might be either 
due to chemotherapy itself or additional effects. This finding is in line with data 
from literature showing additional effects of chemotherapy in cases under 
antibiotic treatment [VAN VLIET et al., 2009]. Abundance of Clostridium cluster 
IV did not differ significantly under antibiotic use, while the diversity did 
decrease. Principal component analysis of PCR DGGE fingerprints showed 
grouping of patients under antibiotic treatment.  
 
High-throughput sequencing 
Our qPCR results showed that the emergence of C. difficile in oncology patients 
P09 and P11 in point in time T01 immediately after chemotherapy went along 
with a decline of the genera Bifidobacterium, Lactobacillus and Clostridium 
cluster IV. These samples were of special interest for us and therefore 
submitted to 454 barcode sequencing. Results indicated a dramatically 
decrease of sequences attributable to F. prausnitzii from 9% to zero. F. 
prausnitzii is a commensal antiinflammatory bacterium of the human gut flora. 
Low levels of F. prausnitzii may be associated with Crohn's disease [SOKOL et 
al., 2008]. After chemotherapy facultativ pathogenic Enterococcus faecium 
increased and further less abundant sequences appeared that were not 
detected before treatment: Eggerthella, Megasphaera, Parvimonas, 
Anaerostipes, Eubacterium, Anaerococcus, Methylobacterium, Holdemania, 
Turicibacter, Akkermansia, Sutterella, Sphingomonas, Anaerotruncus, 
Coprococcus, Streptococcus and Dorea. Propionate producing Megasphaera 
spp. and butyrate-producers Anaerostipes caccae and Eubacterium hallii utilize 
lactat [FLYTHE et al., 2010; MARQUET et al., 2009]. Marquet et al. suggested 
that A. caccae and E. hallii compete for lactate with sulfate-reducing bacteria 
and high concentrations of sulfate in the gut epithelium may contribute to bowel 
disease. Microorganisms of the genus Methylobacterium are gram negative, 
facultative methylotrophic, and ubiquitous in nature. They rarely cause human 
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disease, mainly only in subjects with preexisting causes of immune depression 
[FANCI et al., 2010]. Fanci et al. decribed an unusual Methylobacterium 
fujisawaense infection in a patient with acute leukaemia undergoing 
hematopoietic stem cell transplantation. Poorly known Turicibacter spp. was 
previously found in weaned piglets and is known to be susceptible to the 
growth-promoting antibiotic chlortetracycline [RETTEDAL et al., 2009]. In 
humans the genus Turicibacter has been found in the ileal pelvic pouch of a 
former ulcerative colitis patient [FALK et al., 2007]. Akkermansia muciniphila, a 
anaerobic bacterium belonging to the Verrucomicrobia, is specialized in the 
degradation of mucin, the glycoprotein present in mucus, and is found in high 
numbers in the intestinal tract of human and other mammalian species. A. 
muciniphila is suggested to modulate pathways involved in establishing 
homeostasis for basal metabolism and immune tolerance toward commensal 
microbiota [DERRIEN et al., 2011].  Dorea spp. are members of the Clostridium 
coccoides rRNA group of organisms and are mucosa-associated bacteria of the 
human gastrointestinal tract [TARAS et al. 2002; NOMURAS et al., 2005]. 
 
Further research will have to show if the growth of Clostridium difficile is 
associated with the decline of Lactobacillus spp., Bifidobacterium spp. and 
Clostridium cluster IV, especially if there is a causal relationship to the decrease 
of Faecalibacterium prausnitzii. Also, the emergence of C. difficile might result 
in a increase of mucus degrading bacteria such as Akkermansia muciniphila. 
Mucus hypersecretion is a common symptom of bacterial infections of the gut 
epithelium, irritable bowel syndrome and ulcerative colitis. [GOODMAN et al., 
1977; GUIMEAU et al., 2008]. 
 
In previous studies it has been shown that chemotherapeutic treatment is 
associated with a decrease in the microbial diversity and a decline of total 
bacterial counts. Moreover, research has shown that decreasing species 
richness coincides in time with the development of severe chemotherapy-
induced mucositis [VAN VLIET et al., unpublished data]. We observed shifts in 
species composition especially in Clostridium cluster IV, additionally affected by 
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antibiotics. We conclude that antimicrobial treatment significantly reduces the 
diversity of Clostridium cluster IV. Further research is needed to observe 
possible effects of shifts in the gastrointestinal microbiota regarding infection, 
inflammation and the development and maintenance of mucosal barrier 
function. Further investigations will also have to show the clinical relevance of 
restoring dysbalances of the gut microbiota and thereby prevent mucosal barrier 
injury and its complications. Therefore prebiotic, probiotics or synbiotics could 
be used with the consideration for the risk of whole live bacteria used as 
probiotics causing invasive infections in immunocompromised patients.  
 
In conclusion, chemotherapy treatment results in shifts in fecal microbiota, 
which come together with the emergence of Clostridium difficile in some 
patients. These changes affect and alter the functions of the GI microbiota and 
may contribute to severe side effects in oncology patients. 
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11. PROTOCOLS 
11.1. DNA extraction from stool using QIAamp DNA Stool Mini Kit & 
Beadbeating 
All centrifugation steps at max. speed. Prepare: ice. Keep samples always 
frozen. Work with fire and ethanol, spatula and scalpel should be sterilized 
between different samples. Prepare two heat-blocks at 95°C and 70°C. If a 
precipitate has formed in ASL buffer or AL buffer, solve in waterbath. Anyways 
vortex well before use. 
1. Weight 180-220 mg frozen sample in a lysing matrix E (soil kit) tube. 
2. Add 1.4 ml ASL buffer. Vortex well. 
3. Secure lysing matrix tubes in beadbeater. Two cycles of 45 sec 
beadbeating with one intervening minute on ice. 
4. Lysis for 5 min at 95°C 
5. Vortex for 15 sec, centrifuge 1 min. 
6. Pipet supernatant in a new 2 ml eppendorf tube. Discard pellet.  
7. Add inhibitEX tablet. Vortex immediately until completely dissolved. 
Incubate 1 min at r/t 
8. Centrifuge 6 min 
9. Pipet supernatant into a clean 1.5 ml eppendorf tube. Discard pellet. 
10. Centrifuge 3 min 
11. Pipet 25µl proteinase K into a clean 2ml tube. 
12. Add supernatant (approx 600µl) 
13. Add 600 µl buffer AL. mind that proteinase K and buffer AL may never 
come directly into contact. Never change the order of steps 11-13. 
14. Incubate 10 min at 70°C 
15. Add 600 µl ethanol (96-100%) to the lysate and mix by vortex. 
16. Label the lid of a new QIAamp spin column provided in a 2 ml collection 
tube. 
17. Carefully apply 600 µl lysate from step 12 to the QIAamp spin column 
without moistening the rim. Centrifuge for 1 min, discard filtrate and place 
the spin column again in the 2 ml collection tube. 
18. Repeat step 17 until all lysate has been used. 
19. Carefully open the spin column and add 500 µl buffer AW1. Centrifuge 1 
min.  
20. Discard flow-through. 
21. Carefully open the spin column and add 500 µl buffer AW2. Centrifuge 3 
min.  
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22. To remove residual buffer AW2, place the spin column into a new 
collection tube and centrifuge for another 1 min 
23. Transfer spin column into a new labelled 1.5 eppendorf tube. Elute with 
200µl RNase, DNase free water, preheated to 80C. Centrifuge 1 min. 
24. Elute a 2nd time with 200 µl H2O (80C). 
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11.2. Cloning protocol 
First two steps: 
 Perform PCR/DGGE with several samples, thereafter choose the sample 
with the most diverse bandpattern 
 Purify PCR products with QIAGEN PCR Purification Kit 
First Day 
1. Prepare a ligation-reaction mixture according to the following scheme 
with the control (included in Kit) and the purified sample: promega pGEM-T 
Easy Vector System l 
 
                                                                         
 
 
 
2. Prepare for the next day:  
 Prepare 4 LB/Ampicillin/IPTG/X-Gal plates for each ligation reaction  
           + 1 plate for determining transformation efficiency 
 
 LB solid media: Mix for 500ml LB-plating-media:  
 
5g Tryptophan 
2,5g Yeast Extract 
2,5g NaCl 
7,5g Agar 
 autoklav (1h) 
At 50°C: +1ml Ampicilin 
(50mg/0,5ml) 
 
 Pour plates: 20ml per plate 
7,5µl Buffer 
+1µl Vector 
+1µl Ligase 
+5,5µl PCR pur. Or +3µl of control 
15µl total volume  incubate at 4°C 
over night 
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o Work under a Bunsen burner without gloves with disinfected 
hands 
o Avoid air bubbles in the agar by swiveling 
o Let the plates dry over night, thereafter pile upside down in a 
plastic bag 
 
 LB liquid media 100ml 
  
 
 
 
Second Day 
1. Transformation: promega JM109 competent cells (200ml aliquots):  
 Transfer 10µl of the ligation to 100µl competent cells on ice for 1h 
 Heat-Shock: 42°C for 90sec, and immediately 5min on ice. Do not shake! 
 Add 500µl LB media on the competent cells and incubate at 37°C 1h with 
shaking 150rpm 
 Mix the tubes with your snapping finger 
Always work on ice and with cut off pipette tips with competent cells! 
2. Plates: 
 Plate 20µl -IPTG/ X-Gal  
 Plate 100µl of each transformation culture; (2 plates with each100µl), 
plate control just once  
 Dilute and mix the rest with 100µl LB-Media  
 Plate 2 x100µl of each deluted transformation culture 
 Incubate at 37° over night (Incubator)              
 
Third Day 
1. Screening for blue and white colonies 
 Transfer 50 white colonies (have vector and insert) to 50 clean eppendorf 
tubes  containing 40µl TE Buffer 
1g Trypton 
0,5g Yeast extract 
0,5g NaCl 
Fill up with H20 dest. to 100ml and stir 
 Autoklav 1h  
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 Transfer each picked colony to a new plate with 50 marked arrays  
 
 3 cycles of freeze- thawing [-20°C for 20sec  95°C 2 sec] 
 
Forth Day 
 Perform PCRs and gel electrophoresis to check fragment length 
 DGGE 
 Glycerin cultures 
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